Itamar Medical & Roche Sign Agreement For EndoPAT Devices in Preclinical Drug Development
Itamar Medical, a leader in non-invasive vascular health diagnostics, recently announced that an agreement has been signed with Roche by which Itamar will develop an EndoPAT device designated for use with animal models, enabling preclinical studies examining the efficacy of various compounds in the early stage of drug development essential for later stage development in humans. Itamar’s EndoPAT device is a non-invasive technology designed to diagnose and monitor endothelial dysfunction, which constitutes an early stage of cardiovascular diseases in humans.
“Following on from our work with Roche in clinical studies, we are pleased to further our collaboration that will reinforce our strategy of EndoPAT playing a major role in developing personalized medicine and companion diagnostics,” said Dr. Dov Rubin, Itamar Medical’s President and CEO.
“EndoPAT offers the only non-invasive, FDA-cleared technology for detecting endothelial dysfunction that is easily applied and totally operator independent in humans,” added Dr. Koby Sheffy, Itamar Medical’s CTO and Senior Vice President. “This advanced development positions the EndoPAT to be the technology of choice to assess endothelial dysfunction in cardiovascular drugs development from the early animal model through the different clinical phase trials in humans.”
Itamar Medical Ltd. is a publicly traded medical technology company utilizing PAT (Peripheral Arterial Tone) signal technology and applications. The PAT signal is a non-invasive “window” to both the cardiovascular and autonomic nervous systems. Itamar Medical is the developer of EndoPAT, which diagnoses endothelial dysfunction, an important state in the development and progress of atherosclerosis affecting both early and late stages of the disease. EndoPAT has now been deployed by over 10 pharmaceutical companies, many of which are among the Fortune 100, in nearly 20 large-scale drug development studies, and has been proven to shorten the time and reduce the cost of drug development.
Total Page Views: 1168
